ra 2

RA-2 is a pan-negative-gating modulator of KCa2 3 channels that acts by inhibiting EDH-type relaxation in coronary arteries.

Ginsenoside Ra2(人参皂苷 Ra2)是一种在人参中发现的天然产物，对Angiotensin-converting enzyme具有抑制活性（IC50= 385.59 µM）。

CCR2-RA-[R] 是一种 C-C 趋化因子受体 2 型 (CCR2) 变构拮抗剂，IC50值为103 nM。

RA 263 is a nucleoside.

IDRA-21 是一种阳性 AMPA 受体调节剂。

Abexinostat (PCI24781) 是一种新型的泛HDAC 抑制剂，对HDAC1的Ki 值为7 nM。

AR-A 2 is a selective 5-HT1B receptor antagonist, with a high affinity to guinea pig cortex 5HT1B 1D and recombinant guinea pig 5-HT1B receptors (Ki: 0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki: 5 nM).

AB928 是可口服的选择性腺苷受体(A2aR A2bR)双拮抗剂，可减轻腺苷介导的免疫抑制，具有免疫调节和抗肿瘤活性。

Tetrahexyldecyl ascorbate（四己基癸醇​​抗坏血酸酯,BV-OSC）是抗坏血酸的亲脂性前体，是一种更稳定和更易渗透的维生素 C，是抗光老化和抗色素沉着的强效抗氧化剂，能够抑制MMP酶的活性。

meso-Tetra-(2-thienyl)porphine是一种合成的卟啉产品，具有通过DNA大分子的外部沟槽（小沟槽）的次级相互作用进行DNA结合的能力。此外，meso-Tetra-(2-thienyl)porphine还展现出电化学氧化还原特性。

ADORA2A PDE4D-IN-1 (Compound 9) 是一种腺苷 A2a 受体（ADORA2A）和磷酸二酯酶 4D（PDE4D）的双重抑制剂，适用于支气管哮喘研究。

UCF 101 是竞争性的促凋亡蛋白酶Omi HtrA2选择性抑制剂。它对 MI R 损伤具有明显的心脏保护作用，还具有一定的神经保护作用。它在 543 nm 处具有天然的红色荧光，可用于监视其进入哺乳动物细胞的能力。

CRA-2059 hydrochloride is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ)[1][2]. Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 hydrochloride has the potential for inflammatory bowel disease research[1]. [1]. Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002;16(3):407-413.[2]. Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384(12):1605-1611.

CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ)[1][2]. Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 has the potential for inflammatory bowel disease research[1]. [1]. Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002;16(3):407-413.[2]. Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384(12):1605-1611.

CRA-2059 is a potent and selective inhibitor of tryptase, particularly targeting recombinant human tryptase-β (rHTβ), with a K i of 620 pM.

DORA-22 是一种双食欲素受体拮抗剂，可改善轻度压力引起的失眠，对记忆的影响很小。

3-Acetoxy-24-hydroxydammara-20,25-diene 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN2914，CAS号为 143519-04-4。

Timapiprant sodium inhibits mast cell activation of Th2 lymphocytes and eosinophils. Timapiprant sodium is a potent and selective D prostanoid receptor 2 antagonist. Timapiprant sodium potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), ra

Bz-rA Phosphoramidite is used for ribonucleotides modification[1]. [1]. Elise Malek-Adamian, et al. 4'-C-Methoxy-2'-deoxy-2'-fluoro Modified Ribonucleotides Improve Metabolic Stability and Elicit Efficient RNAi-Mediated Gene Silencing. J Am Chem Soc. 2017 Oct 18;139(41):14542-14555.

IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2].

NF-κB MAPK-IN-1 是一种有效的 NF-κB 和 MAPK 通路双重抑制剂，具有潜在的抗炎活性，抑制 NO 生成，对 LPS 诱导的iNOS，COX-2，ERΚ和P38激活有抑制作用。 NF-κB MAPK-IN-1 可用于预防和治疗类风湿关节炎 (RA) 。

AFM-30a hydrochloride 是一种有效的、高度选择性的蛋白质精氨酸脱亚胺酶 2(PAD2) 抑制剂。AFM-30a hydrochloride 能够与 PAD2 结合 (EC50: 9.5 μM)，也能够抑制 H3 瓜氨酸化 (EC50: 0.4 μM)。AFM-30a hydrochloride 能够用于研究某些癌症和多种自身免疫性疾病如类风湿性关节炎 (RA)、多发性硬化症、狼疮和溃疡性结肠炎。

BMS-681 is an orthosteric antagonist of chemokine receptor 2 (CCR2) that forms a ternary complex with CCR2 and its allosteric antagonist, CCR2-RA-[R]. Together, the complex inhibits chemokine binding with BVMS-681 in the orthosteric pocket and CCR2-RA-[R] in the intracellular allosteric G-protein binding site. When chemokine binding is inhibited, modulation responses implicated in several inflammatory and neurodegenerative diseases, including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, diabetic nephropathy, and cancer can be controlled. This action occurs as the migration of monocytes, immature dendritic cells, and T-cell subpopulations towards endogenous CC chemokine ligands is mediated.

Cabiralizumab (FPA 008) 是一种抗 CSF1R 单克隆抗体 (MAb)。Cabiralizumab 可增强 T 细胞浸润和抗肿瘤 T 细胞免疫反应。Cabiralizumab 抑制破骨细胞的活化并阻止骨质破坏，可用于类风湿性关节炎 (RA) 的研究。Cabiralizumab 可与 Nivolumab 结合用于肺癌研究。